UGCG and Parkinson disease: For example, Sanofi Genzyme is currently supporting a study (MOVES-PD) of GZ/SAR402671, a glucosylceramide synthase inhibitor, in PD patients carrying aGBA gene mutation (ClinicalTrials.gov, NCT02906020).